RT @CCR_AACR: Phase 3 Study (CheckMate 214): Treatment-free survival over 42 months in advanced renal cell carcinoma. https://t.co/VJ6zB4ex…
RT @DrMeredithGT: ⬆️ Treatment-free survival (TFS) w/ NIVO+IPI vs sunitinib *without* ⬆️ toxicity in #CheckMate214 @OncoAlert
RT @DrMeredithGT: ⬆️ Treatment-free survival (TFS) w/ NIVO+IPI vs sunitinib *without* ⬆️ toxicity in #CheckMate214 @OncoAlert
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial https://t.co/5a7ZPoARln
⬆️ Treatment-free survival (TFS) w/ NIVO+IPI vs sunitinib *without* ⬆️ toxicity in #CheckMate214 @OncoAlert
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial | Clinical Cancer Research https://t.co/23R7eyK0d7
RT @drenriquegrande: ⚡️ Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell C…
RT @CCR_AACR: Phase 3 Study (CheckMate 214): Treatment-free survival over 42 months in advanced renal cell carcinoma. https://t.co/VJ6zB4ex…
RT @drenriquegrande: ⚡️ Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell C…
Phase 3 Study (CheckMate 214): Treatment-free survival over 42 months in advanced renal cell carcinoma. https://t.co/VJ6zB4exgO https://t.co/GG6QEOmMkF
⚡️ Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial #kidneycancer #immunotherapy https://t.co/dE6Nd8Fv3S https://t.co/5tZj5BnT1b
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial | Clinical Cancer Research https://t.co/23R7eyK0d7
RT @weoncologists: Just Out @CCR_AACR 🚨 #CheckMate242 Pts discontinuing IO may have periods of disease control w/o need for ongoing tx ⚠️…
RT @weoncologists: Just Out @CCR_AACR 🚨 #CheckMate242 Pts discontinuing IO may have periods of disease control w/o need for ongoing tx ⚠️…
RT @OncoAlert: Just Out @CCR_AACR 🚨 #CheckMate242
RT @weoncologists: Just Out @CCR_AACR 🚨 #CheckMate242 Pts discontinuing IO may have periods of disease control w/o need for ongoing tx ⚠️…
RT @weoncologists: Just Out @CCR_AACR 🚨 #CheckMate242 Pts discontinuing IO may have periods of disease control w/o need for ongoing tx ⚠️…
RT @weoncologists: Just Out @CCR_AACR 🚨 #CheckMate242 Pts discontinuing IO may have periods of disease control w/o need for ongoing tx ⚠️…
RT @weoncologists: Just Out @CCR_AACR 🚨 #CheckMate242 Pts discontinuing IO may have periods of disease control w/o need for ongoing tx ⚠️…
RT @weoncologists: Just Out @CCR_AACR 🚨 #CheckMate242 Pts discontinuing IO may have periods of disease control w/o need for ongoing tx ⚠️…
RT @weoncologists: Just Out @CCR_AACR 🚨 #CheckMate242 Pts discontinuing IO may have periods of disease control w/o need for ongoing tx ⚠️…
RT @OncoAlert: Just Out @CCR_AACR 🚨 #CheckMate242 https://t.co/rBATjy4QZt
RT @weoncologists: Just Out @CCR_AACR 🚨 #CheckMate242 Pts discontinuing IO may have periods of disease control w/o need for ongoing tx ⚠️…
RT @weoncologists: Just Out @CCR_AACR 🚨 #CheckMate242 Pts discontinuing IO may have periods of disease control w/o need for ongoing tx ⚠️…
RT @OncoAlert: Just Out @CCR_AACR 🚨 #CheckMate242 https://t.co/rBATjy4QZt
Just Out @CCR_AACR 🚨 #CheckMate242
RT @weoncologists: Just Out @CCR_AACR 🚨 #CheckMate242 Pts discontinuing IO may have periods of disease control w/o need for ongoing tx ⚠️…
RT @weoncologists: Just Out @CCR_AACR 🚨 #CheckMate242 Pts discontinuing IO may have periods of disease control w/o need for ongoing tx ⚠️…
RT @weoncologists: Just Out @CCR_AACR 🚨 #CheckMate242 Pts discontinuing IO may have periods of disease control w/o need for ongoing tx ⚠️…
RT @weoncologists: Just Out @CCR_AACR 🚨 #CheckMate242 Pts discontinuing IO may have periods of disease control w/o need for ongoing tx ⚠️…
RT @weoncologists: Just Out @CCR_AACR 🚨 #CheckMate242 Pts discontinuing IO may have periods of disease control w/o need for ongoing tx ⚠️…
RT @weoncologists: Just Out @CCR_AACR 🚨 #CheckMate242 Pts discontinuing IO may have periods of disease control w/o need for ongoing tx ⚠️…
Just Out @CCR_AACR 🚨 #CheckMate242 Pts discontinuing IO may have periods of disease control w/o need for ongoing tx ⚠️ TOX may persist Pts starting1️⃣st line nivolumab+ ipilimumab🧪for #KidneyCancer had more survival time tx free w/o TOX🆚 sunitinib 💊 ht
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial https://t.co/RUOHzHWa06
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial https://t.co/sMWvCXad6l
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma. #RCC https://t.co/9ZfYLttNgM
Nivolumab + ipilimumab vs sunitinib - prolongs treatment-free survival in advanced renal cell carcinoma- CheckMate 214 https://t.co/yKUq5xESqo https://t.co/QvMOZz7dXX
RT @docjavip: Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma:…
RT @docjavip: Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma:…
RT @docjavip: Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma:…
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial | Clinical Cancer Research https://t.co/dFkJuhVb1I
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial https://t.co/6o7Yu5qFl6
RT @TiansterZhang: Pleased to see the treatment free survival (TFS) analysis from #checkmate214 fully published @CCR_AACR from @Merregan #D…
RT @TiansterZhang: Pleased to see the treatment free survival (TFS) analysis from #checkmate214 fully published @CCR_AACR from @Merregan #D…
RT @TiansterZhang: Pleased to see the treatment free survival (TFS) analysis from #checkmate214 fully published @CCR_AACR from @Merregan #D…
RT @TiansterZhang: Pleased to see the treatment free survival (TFS) analysis from #checkmate214 fully published @CCR_AACR from @Merregan #D…
RT @TiansterZhang: Pleased to see the treatment free survival (TFS) analysis from #checkmate214 fully published @CCR_AACR from @Merregan #D…
RT @TiansterZhang: Pleased to see the treatment free survival (TFS) analysis from #checkmate214 fully published @CCR_AACR from @Merregan #D…
RT @TiansterZhang: Pleased to see the treatment free survival (TFS) analysis from #checkmate214 fully published @CCR_AACR from @Merregan #D…
RT @TiansterZhang: Pleased to see the treatment free survival (TFS) analysis from #checkmate214 fully published @CCR_AACR from @Merregan #D…
RT @TiansterZhang: Pleased to see the treatment free survival (TFS) analysis from #checkmate214 fully published @CCR_AACR from @Merregan #D…
Pleased to see the treatment free survival (TFS) analysis from #checkmate214 fully published @CCR_AACR from @Merregan #DavidMcDermott et al! Important post-hoc analysis for clinicians, informing decisions on IO-holds. Congrats to the team! https://t.co/65k
RT @CellworksLife: Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcin…
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma. #RCC https://t.co/OblObawELL
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial https://t.co/UWoZli7GIi
#OnlineFirst: Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. https://t.co/aKIg5dsUNk https://t.co/CsPGoNHEXe